SAB Biotherapeutics annual current ratio
2020
2021
2022
2023
2024
2025
SAB Biotherapeutics Current Ratio Growth & History (SABS)
SAB Biotherapeutics's current ratio was 9.46 for fiscal 2025.
View full SAB Biotherapeutics company overviewSAB Biotherapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 9.46 | 6.48 | +217.31% |
| 2024 | 2024-12-31 | 2.98 | −2.47 | −45.27% |
| 2023 | 2023-12-31 | 5.45 | 3.97 | +269.63% |
| 2022 | 2022-12-31 | 1.47 | −0.42 | −22.32% |
| 2021 | 2021-12-31 | 1.90 | −1.22 | −39.09% |
| 2020 | 2020-12-31 | 3.11 | — | — |
SAB Biotherapeutics quarterly current ratio
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 9.22 | 8.35 | +957.79% |
| Q1 2026 | 2026-03-31 | 11.45 | 9.76 | +578.09% |
| Q4 2025 | 2025-12-31 | 9.46 | 6.48 | +217.31% |
| Q3 2025 | 2025-09-30 | 10.50 | 6.80 | +184.37% |
| Q2 2025 | 2025-06-30 | 0.87 | −4.37 | −83.37% |
| Q1 2025 | 2025-03-31 | 1.69 | −3.97 | −70.14% |
| Q4 2024 | 2024-12-31 | 2.98 | −2.47 | −45.27% |
| Q3 2024 | 2024-09-30 | 3.69 | 3.35 | +986.86% |
| Q2 2024 | 2024-06-30 | 5.24 | 4.42 | +540.78% |
| Q1 2024 | 2024-03-31 | 5.65 | 4.55 | +413.96% |
| Q4 2023 | 2023-12-31 | 5.45 | 3.97 | +269.63% |
| Q3 2023 | 2023-09-30 | 0.34 | −0.96 | −73.82% |
| Q2 2023 | 2023-06-30 | 0.82 | −0.89 | −52.13% |
| Q1 2023 | 2023-03-31 | 1.10 | −0.83 | −42.99% |
| Q4 2022 | 2022-12-31 | 1.47 | −0.42 | −22.32% |
| Q3 2022 | 2022-09-30 | 1.30 | −1.09 | −45.74% |
| Q2 2022 | 2022-06-30 | 1.71 | −4.42 | −72.11% |
| Q1 2022 | 2022-03-31 | 1.93 | −12.08 | −86.23% |
| Q4 2021 | 2021-12-31 | 1.90 | — | — |
| Q3 2021 | 2021-09-30 | 2.39 | — | — |
| Q2 2021 | 2021-06-30 | 6.13 | — | — |
| Q1 2021 | 2021-03-31 | 14.01 | — | — |
SAB Biotherapeutics current ratio trends
Over the last five fiscal years, SAB Biotherapeutics's current ratio increased from 3.11 to 9.46, a change of 6.35. The latest reported quarter, Q2 2026, shows 9.22.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SAB Biotherapeutics source filings ↗